Research and Markets: AstraZeneca's Tralokinumab (Asthma) - Forecast and Market Analysis to 2023

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/3h3w79/tralokinumab) has announced the addition of the "Tralokinumab (Asthma) - Forecast and Market Analysis to 2023" report to their offering.

AstraZeneca's tralokinumab is in Phase II of development for severe, persistent, uncontrolled asthma despite standard-of-care therapy and failing third-line treatment, such as a high-dose ICS/LABA combination. Tralokinumab is an IgG4 humanized mAb against IL-13, which is a pleiotropic cytokine of the Th2 cell response. IL-13 is a key target for new anti-asthma therapeutic strategies because of its involvement, together with IL-4, in several aspects of airway inflammation and remodeling, including mucus production, IgE synthesis, recruitment of eosinophils and basophils, as well as proliferation of bronchial fibroblasts and airway smooth muscle cells.

Scope

  • Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Tralokinumab including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Tralokinumab for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Unmet Need and Opportunity

7 Pipeline Assessment

8 Tralokinumab

9 Appendix

For more information visit http://www.researchandmarkets.com/research/3h3w79/tralokinumab

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Respiratory

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Respiratory